Patent Search

 
 

Farnesyl protein transferase inhiitors for treating breast cancer

Abstrict

The present invention relates to the use of farnesyl protein transferase inhibitors for preparing pharmaceutical compositions for treating advanced breast cancer.

Claims

7. The use as claimed in claim 2 wherein the compound is (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlor- o-phenyl)-1-methyl-2(1H)-quinolinone; or a pharmaceutically acceptable acid addition salt thereof.

8. The use as claimed in claim 1 wherein the farnesyl protein transferase inhibitor is a compound of formula (IX) wherein .dbd.X.sup.1-X.sup.2-X.su- p.3 is a trivalent radical of formula (x-2), (x-3) or (x-4), >Y1-Y2 is a trivalent radical of formula (y-2), (y-3) or (y-4), r and s are 1, t is 0, R.sup.1 is halo, preferably chloro, and most preferably 3-chloro or R.sup.1 is C.sub.1-4alkyl, preferably 3-methyl, R.sup.2 is halo, preferably chloro, and most preferably 4-chloro, R.sup.3 is a radical of formula (b-1) or (b-3), R.sup.4 is a radical of formula (c-2), R.sup.6 is C.sub.1-4alkyl, R.sup.9 is hydrogen, R.sup.10 and R.sup.11 are hydrogen and R.sup.12 is hydrogen or hydroxy.

9. The use as claimed in claim 1 wherein the farnesyl protein transferase inhibitor is 5-(3-chlorophenyl)-.alpha.-(4-chlorophenyl)-.alpha.-(1-methy- l-1H-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine or a pharmaceutically acceptable acid addition salt thereof.

10. The use as claimed in any one of the preceding claims wherein a therapeutically effective amount of the pharmaceutical composition is administered orally or parenterally.

11. The use as claimed in any of the preceding claims wherein the farnesyl protein transferase inhibitor is administered in combination with a further anti-cancer agent.

12. The use as claimed in claim 11 wherein the further anti-cancer agent is tamoxifen.

13. A method of treating advanced breast cancer in a mammal comprising the steps of administering a therapeutically effective amount of a farnesyl protein transferase inhibitor to said mammal.

Description

[0001] The present invention is concerned with the finding that farnesyl protein transferase inhibitors are useful for preparing a pharmaceutical composition for treating advanced breast cancer.

[0002] Oncogenes frequently encode protein components of signal transduction pathways which lead to stimulation of cell growth and mitogenesis. Oncogene expression in cultured cells leads to cellular transformation, characterized by the ability of cells to grow in soft agar and the growth of cells as dense foci lacking the contact inhibition exhibited by non-transformed cells. Mutation and/or overexpression of certain oncogenes is frequently associated with human cancer. A particular group of oncogenes is known as ras which have been identified in mammals, birds, insects, mollusks, plants, fungi and yeasts. The family of mammalian ras oncogenes consists of three major members ("isoforms"): H-ras, K-ras and N-ras oncogenes. These ras oncogenes code for highly related proteins generically known as p21.sup.ras. Once attached to plasma membranes, the mutant or oncogenic forms of p21.sup.ras will provide a signal for the transformation and uncontrolled growth of malignant tumor cells. To acquire this transforming potential, the precursor of the p21.sup.ras oncoprotein must undergo an enzymatically catalyzed farnesylation of the cysteine residue located in a carboxyl-terminal tetrapeptide. Therefore, inhibitors of the enzyme that catalyzes this modification, farnesyl protein transferase, will prevent the membrane attachment of p21.sup.ras and block the aberrant growth of ras-transformed tumors. Hence, it is generally accepted in the art that farnesyl transferase inhibitors can be very useful as anticancer agents for tumors in which ras contributes to transformation.

[0003] It has been estimated that as many as 30-40% of human tumours may contain a ras mutation, with some tumours, such as colon and lung, showing ras mutations in around 50% and 90% of tumours, respectively. K-ras and Ha-ras mutations have been identified in breast cancer tumours, but at low levels (approximately 5%).

[0004] However, although ras mutations are relatively infrequent in breast cancer, there is evidence to suggest that the pathways which ras services may still be deregulated in breast cancer cells (Clark G J and Der C J, Breast Cancer Res. Treat. 1995. 35 (1). 133-144). Recent identification of many of the components of the ras signal transduction pathway has defined a network of protooncogene proteins controlling diverse signalling events that regulate cell growth and differentiation. Mutations that alter the function of any one component of this signal pathway may trigger the same oncogenic events as a mutation of ras itself. Moreover, ras-related proteins, such as TC21/R-Ras2, have been shown to possess the ability to trigger malignant transformation in MCF-10A human breast epithelial cells lines via signalling pathways shared with ras proteins (Clark G. J. et al, Oncogene, 1996, 12(1), 169-76). Also, TC21 protein expression was found to be greatly elevated in 7 of 9 breast tumour lines when compared to untransformed MCF-10A cells.

[0005] Bland et al (Ann. Surg. 1995, 221(6), 706-18) looked at oncogene protein expression as prognostic discriminants for breast cancer. Of the individual oncogenes examined (c-fos, c-myc, Ha-ras and p53), the presence of Ha-ras and c-fos gave the greatest prediction for poor survival.

[0006] Breast cancer is the most common female malignancy and the main cause of death from cancer in women. Each year approximately 30,000 new cases are diagnosed and there are nearly 16,000 deaths in the UK; about 1 in 12 women sill develop breast cancer at some time in their life.

[0007] Patients with clinically evident distant metastases are still incurable, although the disease may be controlled for periods longer than 5 or 10 years in some patients. However the median survival of all patients with metastatic disease is approximately 2 to 3 years, and the search for additional effective therapies continues.

[0008] Currently patients with indolent disease, i.e. disease characterised by the presence of bone, soft tissue or non-life threatening visceral metastases are generally treated in the first instance with an endocrine therapy, such as an aromatase inhibitor, anti-oestrogen or progestogen. Depending on their response to that therapy, patients may receive further endocrine treatment before being considered for chemotherapy. Patients with aggressive disease, characterised by widespread symptomatic metastases or extensive visceral involvement, will normally be considered for combination therapy, such as FEC or CAF, as a more rapid response is desirable in these patients. Patients who have oestrogen receptor (ER) negative tumours may also be treated in the first instance with chemotherapy, since hormonal therapy is largely ineffective in this group.

[0009] WO-97/21701 describes the preparation, formulation and pharmaceutical properties of farnesyl protein transferase inhibiting (imidazoly-5-yl)methyl-2-quinolinone derivatives of formulas (I), (II) and (III), as well as intermediates of formula (II) and

[0010] (III) that are metabolized in vivo to the compounds of formula (I). The compounds of formulas (I), (II) and (III) are represented by 1

[0011] the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein

[0012] the dotted line represents an optional bond;

[0013] X is oxygen or sulfur;

[0014] R.sup.1 is hydrogen, C.sub.1-12alkyl, Ar.sup.1, Ar.sup.2--C.sub.1-6alkyl, quinolinylC.sub.1-6alkyl, pyridylC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6a- lkyl, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkyl, aminoC.sub.1-6alkyl,

[0015] or a radical of formula -Alk.sup.1-C(.dbd.O)--R.sup.9, -Alk.sup.1-S(O)-R.sup.9 or -Alk.sup.1-S(O).sub.2-R.sup.9,

[0016] wherein Alk.sup.1 is C.sub.1-6alkanediyl,

[0017] R.sup.9 is hydroxy, C.sub.1-6alkyl, C.sub.1-6alkyloxy, amino, C.sub.1-8alkylamino or C.sub.1-8alkylamino substituted with C.sub.1-6alkyloxycarbonyl;

[0018] R.sup.2, R.sup.3 and R.sup.16 each independently are hydrogen, hydroxy, halo, cyano, C.sub.1-6alkyl, C.sub.1-6alkyloxy, hydroxyC.sub.1-6alkyloxy, C.sub.1-6alkyloxyC.sub.1-6alkyloxy, aminoC.sub.1-6alkyl-oxy, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkylox- y, Ar.sup.1, Ar.sup.2C.sub.1-6alkyl, Ar.sup.2oxy, Ar.sup.2C.sub.1-6alkylox- y, hydroxycarbonyl, C.sub.1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C.sub.2-6alkenyl, 4,4-dimethyloxazolyl; or

[0019] when on adjacent positions R.sup.2 and R.sup.3 taken together may form a bivalent radical of formula

--O--CH.sub.2--O-- (a-1),

--O--CH.sub.2--CH.sub.2--O-- (a-2),

--O--CH.dbd.CH-- (a-3),

--O--CH.sub.2--CH.sub.2-- (a-4),

--O--CH.sub.2--CH.sub.2--CH.sub.2-- (a-5), or

--CH.dbd.CH--CH.dbd.CH-- (a-6);

[0020] R.sup.4 and R.sup.5 each independently are hydrogen, halo, Ar.sup.1, C.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1- -6alkyl, C.sub.1-6alkyloxy, C.sub.1-6alkylthio, amino, hydroxycarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylS(O)C.sub.1-6alkyl or C.sub.1-6alkylS(O).sub.2C.sub.1-6alkyl;

[0021] R.sup.6 and R.sup.7 each independently are hydrogen, halo, cyano, C.sub.1-6alkyl, C.sub.1-6alkyloxy, Ar.sup.2oxy, trihalomethyl, C.sub.1-6alkylthio, di(C.sub.1-6alkyl)amino, or

[0022] when on adjacent positions R.sup.6 and R.sup.7 taken together may form a bivalent radical of formula

--O--CH.sub.2--O-- (c-1), or

--CH.dbd.CH--CH.dbd.CH-- (c-2);

[0023] R.sup.8 is hydrogen, C.sub.1-6alkyl, cyano, hydroxycarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylcarbonylC.sub.1-6alkyl, cyanoC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.1-6alkyl, carboxyC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, aminoC.sub.1-6alkyl, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkyl, imidazolyl, haloC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, aminocarbonylC.sub.1-6alkyl, or a radical of formula

--O--R.sup.10 (b-1),

--S--R.sup.10 (b-2),

--N--R.sup.11R.sup.12 (b-3),

[0024] wherein R.sup.10 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, Ar.sup.1, Ar.sup.2C.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.1-6alkyl, or a radical or formula -Alk.sup.2-OR.sup.13 or -Alk.sup.2-NR.sup.14R.sup.15;

[0025] R.sup.11 is hydrogen, C.sub.1-12alkyl, Ar.sup.1 or Ar.sup.2C.sub.1-6alkyl;

[0026] R.sup.12 is hydrogen, C.sub.1-6alkyl, C.sub.1-16alkylcarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylaminocarbonyl, Ar.sup.1, Ar.sup.2C.sub.1-6alkyl, C.sub.1-6alkylcarbonylC.sub.1-6alkyl, a natural amino acid, Ar.sup.1carbonyl, Ar.sup.2C.sub.1-6alkylcarbonyl, aminocarbonylcarbonyl, C.sub.1-6alkyloxyC.sub.1-6alkylcarbonyl, hydroxy, C.sub.1-6alkyloxy, aminocarbonyl, di(C.sub.1-6alkyl)aminoC.sub.1-6alkylca- rbonyl, amino, C.sub.1-6alkylamino, C.sub.1-6alkylcarbonylamino, or a radical or formula -Alk.sup.2-OR.sup.13 or -Alk.sup.2-NR.sup.14R.sup.15;

[0027] wherein Alk.sup.2 is C.sub.1-6alkanediyl;

[0028] R.sup.13 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, hydroxy-C.sub.1-6alkyl, Ar.sup.1 or Ar.sup.2C.sub.1-6alkyl;

[0029] R.sup.14 is hydrogen, C.sub.1-6alkyl, Ar.sup.1 or Ar.sup.2C.sub.1-6alkyl;

[0030] R.sup.15 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, Ar.sup.1 or Ar.sup.2C.sub.1-6alkyl;

[0031] R.sup.17 is hydrogen, halo, cyano, C.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl, Ar.sup.1;

[0032] R.sup.18 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkyloxy or halo;

[0033] R.sup.19 is hydrogen or C.sub.1-6alkyl;

[0034] Ar.sup.1 is phenyl or phenyl substituted with C.sub.1-6alkyl, hydroxy, amino, C.sub.1-6alkyloxy or halo; and

[0035] Ar.sup.2 is phenyl or phenyl substituted with C.sub.1-6alkyl, hydroxy, amino, C.sub.1-6alkyloxy or halo.

[0036] WO-97/16443 concerns the preparation, formulation and pharmaceutical properties of farnesyl protein transferase inhibiting compounds of formula (IV), as well as intermediates of formula (V) and (VI) that are metabolized in vivo to the compounds of formula (IV). The compounds of formulas (IV), (V) and (VI) are represented by 2

[0037] the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein

[0038] the dotted line represents an optional bond;

[0039] X is oxygen or sulfur;

[0040] R.sup.1 is hydrogen, C.sub.1-12alkyl, Ar.sup.1, Ar.sup.2C.sub.1-6alkyl, quinolinylC.sub.1-6alkyl, pyridylC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkyl, aminoC.sub.1-6alkyl,

[0041] or a radical of formula -Alk.sup.1-C(.dbd.O)-R.sup.9, -Alk.sup.1-S(O)-R.sup.9 or -Alk.sup.1-S(O).sub.2-R.sup.9,

[0042] wherein Alk.sup.1 is C.sub.1-6alkanediyl,

[0043] R.sup.9 is hydroxy, C.sub.1-6alkyl, C.sub.1-6alkyloxy, amino, C.sub.1-8alkylamino or C.sub.1-8alkylamino substituted with C.sub.1-6alkyloxycarbonyl;

[0044] R.sup.2 and R.sup.3 each independently are hydrogen, hydroxy, halo, cyano, C.sub.1-6alkyl, C.sub.1-6alkyloxy, hydroxyC.sub.1-6alkyloxy, C.sub.1-6alkyloxyC.sub.1-6alkyloxy, aminoC.sub.1-6alkyloxy, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkyloxy, Ar.sup.1, Ar.sup.2C.sub.1-6alkyl, Ar.sup.2oxy, Ar.sup.2C.sub.1-6alkyloxy, hydroxycarbonyl, C.sub.1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C.sub.2-6alkenyl; or

[0045] when on adjacent positions R.sup.2 and R.sup.3 taken together may form a bivalent radical of formula

--O--CH.sub.2--O-- (a-1),

--O--CH.sub.2--CH.sub.2--O-- (a-2),

--O--CH.dbd.CH-- (a-3),

--O--CH.sub.2--CH.sub.2-- (a-4),

--O--CH.sub.2--CH.sub.2--CH.sub.2-- (a-5), or

--CH.dbd.CH--CH.dbd.CH-- (a-6);

[0046] R.sup.4 and R.sup.5 each independently are hydrogen, Ar.sup.1, C.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxy, C.sub.1-6alkylthio, amino, hydroxycarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylS(O)C.sub.1-6alkyl or C.sub.1-6alkylS(O).sub.2C.sub.1-6alky- l;

[0047] R.sup.6 and R.sup.7 each independently are hydrogen, halo, cyano, C.sub.1-6alkyl, C.sub.1-6alkyloxy or Ar.sup.2oxy;

[0048] R.sup.8 is hydrogen, C.sub.1-6alkyl, cyano, hydroxycarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylcarbonylC.sub.1-6alkyl, cyanoC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.1-6alkyl, hydroxycarbonylC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, aminoC.sub.1-6alkyl, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkyl, haloC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, aminocarbonylC.sub.1-6alkyl, Ar.sup.1, Ar.sup.2C.sub.1-6alkyloxyC.sub.1-6- alkyl, C.sub.1-6alkylthioC.sub.1-6alkyl;

[0049] R.sup.10 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkyloxy or halo;

[0050] R.sup.11 is hydrogen or C.sub.1-6alkyl;

[0051] Ar.sup.1 is phenyl or phenyl substituted with C.sub.1-6alkyl,hydroxy, amino, C.sub.1-6alkyloxy or halo;

[0052] Ar.sup.2 is phenyl or phenyl substituted with C.sub.1-6alkyl,hydroxy,amino,C.sub.1-6alkyloxy or halo.

[0053] WO-98/40383 concerns the preparation, formulation and pharmaceutical properties of farnesyl protein transferase inhibiting compounds of formula (VII) 3

[0054] the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein

[0055] the dotted line represents an optional bond;

[0056] X is oxygen or sulfur;

[0057] --A-- is a bivalent radical of formula

--CH.dbd.CH-- (a-1),

--CH.sub.2--CH.sub.2-- (a-2),

--CH.sub.2--CH.sub.2--CH.sub.2-- (a-3),

--CH.sub.2--O-- (a-4),

--CH.sub.2--CH.sub.2--O-- (a-5),

--CH.sub.2--S-- (a-6),

--CH.sub.2--CH.sub.2--S-- (a-7),

--CH.dbd.N-- (a-8),

--N.dbd.N-- (a-9), or

--CO--NH-- (a-10):

[0058] wherein optionally one hydrogen atom may be replaced by C.sub.1-4alkyl or Ar.sup.1;

[0059] R.sup.1 and R.sup.2 each independently are hydrogen, hydroxy, halo, cyano, C.sub.1-6alkyl, trihalomethyl, trihalomethoxy, C.sub.2-6alkenyl, C.sub.1-6alkyloxy, hydroxyC.sub.1-6alkyloxy, C.sub.1-6alkyloxyC.sub.1-6al- kyloxy, C.sub.1-6alkyloxycarbonyl, aminoC.sub.1-6alkyloxy, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkyloxy, Ar.sup.2 , Ar.sup.2--C.sub.1-6alkyl, Ar.sup.2-oxy, Ar.sup.2--C.sub.1-6alkyloxy; or when on adjacent positions R.sup.1 and R.sup.2 taken together may form a bivalent radical of formula

--O--CH.sub.2--O-- (b-1),

--O--CH.sub.2--CH.sub.2--O-- (b-2),

--O--CH.dbd.CH-- (b-3),

--O--CH.sub.2--CH.sub.2-- (b-4),

--O--CH.sub.2--CH.sub.2--CH.sub.2-- (b-5), or

--CH.dbd.CH--CH.dbd.CH-- (b-6);

[0060] R.sup.3 and R.sup.4 each independently are hydrogen, halo, cyano, C.sub.1-6alkyl, C.sub.1-6alkyloxy, Ar.sup.3-oxy, C.sub.1-6alkylthio, di(C.sub.1-6alkyl)amino, trihalomethyl, trihalomethoxy, or

[0061] when on adjacent positions R.sup.3 and R.sup.4 taken together may form a bivalent radical of formula

--O--CH.sub.2--O-- (C-1),

--O--CH.sub.2--CH.sub.2--O-- (c-2), or

--CH.dbd.CH--CH.dbd.CH-- (c-3);

[0062] R.sup.5 is a radical of formula 4

[0063] wherein R.sup.13 is hydrogen, halo, Ar.sup.4, C.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxy, C.sub.1-6alkylthio, amino, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylS(O)C.sub.1-6alkyl or C.sub.1-6alkylS(O).sub.2C.sub.1-6alky- l;

[0064] R.sup.14 is hydrogen, C.sub.1-6alkyl or di(C.sub.1-4alkyl)aminosulf- onyl;

[0065] R.sup.6 is hydrogen, hydroxy, halo, C.sub.1-6alkyl, cyano, haloC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, cyanoC.sub.1-6alkyl, aminoC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkylthioC.sub.1-6alkyl, aminocarbonylC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.1-6alkyl, C.sub.1-6alkylcarbonylC.sub.1-6a- lkyl, C.sub.1-6alkyloxycarbonyl, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6- alkyl, Ar.sup.5, Ar.sup.5--C.sub.1-6alkyloxyC.sub.1-6alkyl; or a radical of formula

--O--R.sup.7 (e-1),

--S--R.sup.7 (e-2),

--N--R.sup.8R.sup.9 (e-3),

[0066] wherein R.sup.7 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, Ar.sup.6, Ar.sup.6--C.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.1-6alkyl, or a radical of formula -Alk-OR.sup.10 or -Alk-NR.sup.11R.sup.12;

[0067] R.sup.8 is hydrogen, C.sub.1-6alkyl, Ar.sup.7 or Ar.sup.7--C.sub.1-6alkyl;

[0068] R.sup.9 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylaminocarbonyl, Ar.sup.8, Ar.sup.8--C.sub.1-6alkyl, C.sub.1-6alkylcarbonylC.sub.1-6alkyl, Ar.sup.8-carbonyl, Ar.sup.8--C.sub.1-6alkylcarbonyl, aminocarbonylcarbonyl, C.sub.1-6alkyloxyC.sub.1-6alkylcarbonyl, hydroxy, C.sub.1-6alkyloxy, aminocarbonyl, di(C.sub.1-6alkyl)aminoC.sub.1-6alkylca- rbonyl, amino, C.sub.1-6alkylamino, C.sub.1-6alkylcarbonylamino, or a radical or formula -Alk-OR.sup.10 or -Alk-NR.sup.11R.sup.12;

[0069] wherein Alk is C.sub.1-6alkanediyl;

[0070] R.sup.10 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, hydroxyC.sub.1-6alkyl, Ar.sup.9 or Ar.sup.9--C.sub.1-6alkyl;

[0071] R.sup.11 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, Ar.sup.10 or Ar.sup.10--C.sub.1-6alkyl:

[0072] R.sup.12 is hydrogen, C.sub.1-6alkyl, Ar.sup.11 or Ar.sup.11--C.sub.1-6alkyl; and

[0073] Ar.sup.1 to Ar.sup.11 are each independently selected from phenyl; or phenyl substituted with halo, C.sub.1-6alkyl, C.sub.1-6alkyloxy or trifluoromethyl.

[0074] WO-98/49157 concerns the preparation, formulation and pharmaceutical properties of farnesyl protein transferase inhibiting compounds of formula (VIII) 5

[0075] the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein

[0076] the dotted line represents an optional bond;

[0077] X is oxygen or sulfur;

[0078] R.sup.1 and R.sup.2 each independently are hydrogen, hydroxy, halo, cyano, C.sub.1-6alkyl, trihalomethyl, trihalomethoxy, C.sub.2-6alkenyl, C.sub.1-6alkyloxy, hydroxyC.sub.1-6alkyloxy, C.sub.1-6alkyloxyC.sub.1-6al- kyloxy, C.sub.1-6alkyloxycarbonyl, aminoC.sub.1-6alkyloxy, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkyloxy, Ar.sup.1, Ar.sup.1C.sub.1-6alkyl, Ar.sup.1oxy or Ar.sup.1C.sub.1-6alkyloxy;

[0079] R.sup.3 and R.sup.4 each independently are hydrogen, halo, cyano, C.sub.1-6alkyl, C.sub.1-6alkyloxy, Ar.sup.1oxy, C.sub.1-6alkylthio, di(C.sub.1-6alkyl)amino, trihalomethyl or trihalomethoxy;

[0080] R.sup.5 is hydrogen, halo, C.sub.1-6alkyl, cyano, haloC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, cyanoC.sub.1-6alkyl, aminoC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkylthioC.sub.1-6alkyl, aminocarbonylC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.1-6alkyl, C.sub.1-6alkylcarbonylC.sub.1-6a- lkyl, C.sub.1-6alkyloxycarbonyl, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6- alkyl, Ar.sup.1, Ar.sup.1C.sub.1-6alkyloxyC.sub.1-6alkyl; or a radical of formula

--O--R.sup.10 (a-1),

--S--R.sup.10 (a-2),

--N--R.sup.11R.sup.12 (a-3),

[0081] wherein R.sup.10 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, Ar.sup.1, Ar.sup.1C.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.1-6alkyl, or a radical of formula -Alk-OR.sup.13 or -Alk-NR.sup.14R.sup.15;

[0082] R.sup.11 is hydrogen, C.sub.1-6alkyl, Ar.sup.1 or Ar.sup.1C.sub.1-6alkyl;

[0083] R.sup.12 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylaminocarbonyl, Ar.sup.1, Ar.sup.1C.sub.1-6alkyl, C.sub.1-6alkylcarbonylC.sub.1-6alkyl, Ar.sup.1carbonyl, Ar.sup.1C.sub.1-6alkylcarbonyl, aminocarbonylcarbonyl, C.sub.1-6alkyloxyC.sub.1-6alkylcarbonyl, hydroxy, C.sub.1-6alkyloxy, aminocarbonyl, di(C.sub.1-6alkyl)aminoC.sub.1-6alkylcarbonyl, amino, C.sub.1-6alkylamino, C.sub.1-6alkylcarbonylamino,

[0084] or a radical or formula -Alk-OR.sup.13 or -Alk-NR.sup.14R.sup.15;

[0085] wherein Alk is C.sub.1-6alkanediyl;

[0086] R.sup.13 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, hydroxyC.sub.1-6alkyl, Ar.sup.1 or Ar.sup.1C.sub.1-6alkyl;

[0087] R.sup.14 is hydrogen, C.sub.1-6alkyl, Ar.sup.1 or Ar.sup.1C.sub.1-6alkyl;

[0088] R.sup.15 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, Ar.sup.1 or Ar.sup.1C.sub.1-6alkyl;

[0089] R.sup.6 is a radical of formula 6

[0090] wherein R.sup.16is hydrogen, halo, Ar.sup.1, C.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxy, C.sub.1-6alkylthio, amino, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylthioC.sub.1-6alkyl, C.sub.1-6alkylS(O)C.sub.1-6alkyl or C.sub.1-6alkylS(O).sub.2C.sub.1-6alkyl;

[0091] R.sup.17 is hydrogen, C.sub.1-6alkyl or di(C.sub.1-4alkyl)aminosulf- onyl;

[0092] R.sup.7 is hydrogen or C.sub.1-6alkyl provided that the dotted line does not represent a bond;

[0093] R.sup.8 is hydrogen, C.sub.1-6alkyl or Ar.sup.2CH.sub.2 or Het.sup.1CH.sub.2;

[0094] R.sup.9 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkyloxy or halo; or

[0095] R.sup.8 and R.sup.9 taken together to form a bivalent radical of formula

--CH.dbd.CH-- (c-1),

--CH.sub.2--CH.sub.2-- (c-2),

--CH.sub.2--CH.sub.2--CH.sub.2-- (c-3),

--CH.sub.2--O-- (c-4), or

--CH.sub.2--CH.sub.2--O-- (c-5);

[0096] Ar.sup.1 is phenyl; or phenyl substituted with 1 or 2 substituents each independently selected from halo, C.sub.1-6alkyl, C.sub.1-6alkyloxy or trifluoromethyl;

[0097] Ar.sup.2 is phenyl; or phenyl substituted with 1 or 2 substituents each independently selected from halo, C.sub.1-6alkyl, C.sub.1-6alkyloxy or trifluoromethyl; and

[0098] Het.sup.1 is pyridinyl; pyridinyl substituted with 1 or 2 substituents each independently selected from halo, C.sub.1-6alkyl, C.sub.1-6alkyloxy or trifluoromethyl.

[0099] WO-00/39082 concerns the preparation, formulation and pharmaceutical properties of farnesyl protein transferase inhibiting compounds of formula (IX) 7

[0100] or the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein

[0101] .dbd.X.sup.1-X.sup.2-X.sup.3- is a trivalent radical of formula

.dbd.N--CR.sup.6.dbd.CR.sup.7-- (x-1),

.dbd.N--N.dbd.CR.sup.6 -- (x-2),

.dbd.N--NH--C(.dbd.O)-- (x-3),

.dbd.N--N.dbd.N-- (x-4),

.dbd.N--CR.sup.6.dbd.N-- (x-5),

.dbd.CR.sup.6--CR.sup.7.dbd.CR.sup.8-- (x-6),

.dbd.CR.sup.6--N.dbd.CR.sup.7-- (x-7),

.dbd.CR.sup.6--NH--C(.dbd.O)-- (x-8), or

.dbd.CR.sup.6--N.dbd.N-- (x-9);

[0102] wherein each R.sup.6, R.sup.7 and R.sup.8 are independently hydrogen, C.sub.1-4alkyl, hydroxy, C.sub.1-4alkyloxy, aryloxy, C.sub.1-4alkyloxycarbonyl, hydroxyC.sub.1-4alkyl, C.sub.1-4alkyloxyC.sub.- 1-4alkyl, mono- or di(C.sub.1-4alkyl)aminoC.sub.1-4alkyl, cyano, amino, thio, C.sub.1-4alkylthio, arylthio or aryl;

[0103] >Y.sup.1-Y.sup.2- is a trivalent radical of formula

>CH--CHR.sup.9-- (y-1),

>C.dbd.N-- (y-2),

>CH--NR.sup.9-- (y-3), or

>C.dbd.CR.sup.9-- (y-4);

[0104] wherein each R.sup.9 independently is hydrogen, halo, halocarbonyl, aminocarbonyl, hydroxyC.sub.1-4alkyl, cyano, carboxyl, C.sub.1-4alkyl, C.sub.1-4alkyloxy, C.sub.1-4alkyloxyC.sub.1-4alkyl, C.sub.1-4alkyloxycarbonyl, mono- or di(C.sub.1-4alkyl)amino, mono- or di(C.sub.1-4alkyl)aminoC.sub.1-4alkyl, aryl;

[0105] r and s are each independently 0, 1, 2, 3, 4 or 5;

[0106] t is 0, 1, 2 or 3;

[0107] each R.sup.1 and R.sup.2 are independently hydroxy, halo, cyano, C.sub.1-6alkyl, trihalomethyl, trihalomethoxy, C.sub.2-6alkenyl, C.sub.1-6alkyloxy, hydroxyC.sub.1-6alkyloxy, C.sub.1-6alkylthio, C.sub.1-6alkyloxyC.sub.1-6alkyloxy, C.sub.1-6alkyloxycarbonyl, aminoC.sub.1-6alkyloxy, mono- or di(C.sub.1-6alkyl)amino, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkyloxy, aryl, arylC.sub.1-6alkyl, aryloxy or arylC.sub.1-6alkyloxy, hydroxycarbonyl, C.sub.1-6alkyloxycarbonyl, aminocarbonyl, aminoC.sub.1-6alkyl, mono- or di(C.sub.1-6alkyl)aminocarbonyl, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-- 6alkyl; or

[0108] two R.sup.1 or R.sup.2 substituents adjacent to one another on the phenyl ring may independently form together a bivalent radical of formula

--O--CH.sub.2--O-- (a-1),

--O--CH.sub.2--CH.sub.2--O-- (a-2),

--O.dbd.CH.dbd.CH-- (a-3),

--O--CH.sub.2--CH.sub.2-- (a-4),

--O--CH.sub.2--CH.sub.2--CH.sub.2-- (a-5), or

--CH.dbd.CH--CH.dbd.CH-- (a-6);

[0109] R.sup.3 is hydrogen, halo, C.sub.1-6alkyl, cyano, haloC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, cyanoC.sub.1-6alkyl, aminoC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkylthioC.sub.1-6alkyl, aminocarbonylC.sub.1-6alkyl, hydroxycarbonyl, hydroxycarbonylC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl- C.sub.1-6alkyl, C.sub.1-6alkylcarbonylC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl, aryl, arylC.sub.1-6alkyloxyC.sub.1-6alkyl, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkyl:

[0110] or a radical of formula

--O--R.sup.10 (b-1),

--S--R.sup.10 (b-2),

--NR.sup.11R.sup.12 (b-3),

[0111] wherein R.sup.10 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, aryl, arylC.sub.1-6alkyl, C.sub.1-6alkyloxycarbon- ylC.sub.1-6alkyl, or a radical of formula -Alk-OR.sup.13 or -Alk-NR.sup.14R.sup.15;

[0112] R.sup.11 is hydrogen, C.sub.1-6alkyl, aryl or arylC.sub.1-6alkyl;

[0113] R.sup.12 is hydrogen, C.sub.1-6alkyl, aryl, hydroxy, amino, C.sub.1-6alkyloxy, C.sub.1-6alkylcarbonylC.sub.1-6alkyl, arylC.sub.1-6alkyl, C.sub.1-6alkylcarbonylamino, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkylcarbonyl, aminocarbonyl, arylcarbonyl, haloC.sub.1-6alkylcarbonyl, arylC.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkyloxyC.sub.1-6alkylcarbonyl, mono- or di(C.sub.1-6alkyl)aminocarbonyl wherein the alkyl moiety may optionally be substituted by one or more substituents independently selected from aryl or C.sub.1-3alkyloxycarbonyl, aminocarbonylcarbonyl, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkylcarbonyl, or a radical or formula -Alk-OR.sup.13 or -Alk-NR.sup.14R.sup.15;

[0114] wherein Alk is C.sub.1-6alkanediyl;

[0115] R.sup.13 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, hydroxyC.sub.1-6alkyl, aryl or arylC.sub.1-6alkyl;

[0116] R.sup.14 is hydrogen, C.sub.1-6alkyl, aryl or arylC.sub.1-6alkyl;

[0117] R.sup.15 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, aryl or arylC.sub.1-6alkyl;

[0118] R.sup.4 is a radical of formula 8

[0119] wherein R.sup.16 is hydrogen, halo, aryl, C.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxy, C.sub.1-6alkylthio, amino, mono- or di(C.sub.1-4alkyl)amino, hydroxycarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylthioC.sub.1-6alkyl, C.sub.1-6alkylS(O)C.sub.1-6alkyl or C.sub.1-6alkylS(O).sub.2C.sub.1-6alkyl;

[0120] R.sup.16 may also be bound to one of the nitrogen atoms in the imidazole ring of formula (c-1) or (c-2), in which case the meaning of R.sup.16 when bound to the nitrogen is limited to hydrogen, aryl, C.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylS(O)C.sub.1-6alkyl or C.sub.1-6alkylS(O).sub.2C.sub.1-6alkyl;

[0121] R.sup.17 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alk- yl, arylC.sub.1-6alkyl, trifluoromethyl or di(C.sub.1-4alkyl)aminosulfonyl- ;

[0122] R.sup.5 is C.sub.1-6alkyl , C.sub.1-6alkyloxy or halo;

[0123] aryl is phenyl, naphthalenyl or phenyl substituted with 1 or more substituents each independently selected from halo, C.sub.1-6alkyl, C.sub.1-6alkyloxy or trifluoromethyl.

[0124] Other useful farnesyl protein transferase inhibitors include Arglabin (i.e.1(R)-10-epoxy-5(S), 7(S)-guaia-3(4), 11(13)-dien-6, 12-olide descibed in WO-98/28303 (NuOncology Labs); perrilyl alcohol described in WO-99/45912 (Wisconsin Genetics); SCH-66336, i.e. (+)-(R)-4-[2-[4-(3, 10-dibromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohe- pta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamid- e, described in U.S. Pat. No. 5,874,442 (Schering); L778123, i.e. 1-(3-chlorophenyl)-4-[I1(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinon- e, described in WO-00/01691 (Merck); compound 2(S)-[2(S)-[2(R)-amino-3-mer- capto]propylamino-3(S)-methyl]-pentyloxy-3-phenylpropionyl-methionine sulfone described in WO-94/10138 (Merck); and BMS 214662, i.e. (R)-2,3,4,5-tetrahydro-1-(IH-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-t- hienylsulphonyl)-1H- 1,4-benzodiazapine-7-carbonitrile, described in WO 97/30992 (Bristol Myers Squibb) and Pfizer compounds (A) and (B) described in WO-00/12498 and WO-00/12499: 9

[0125] Unexpectedly, we have now found that a farnesyl protein transferase inhibitor has clinical activity in advanced breast cancer. This effect is especially surprising as treatment with the farnesyl protein transferase inhibitor results in shrinkage of the tumor rather than simply delaying tumor progression. This effect is in contrast to the suggestion in Rowinsky et al, Journal of Clinical Oncology, Vol 17, No. 11 (November), 1999, pages 3631-3652 at page 3646 that tumor growth inhibition or "cytostasis" may be the principal therapeutic effect of FTase inhibitors.

[0126] The present invention is concerned with the use of at least a farnesyl protein transferase inhibitor for the preparation of a pharmaceutical composition for treating advanced breast cancer. The term "advanced breast cancer" is used herein to denote breast cancer which has not responded to previous treatment, or which has recurred following such treatment, and also breast cancer in patients who present with metastatic disease at diagnosis.

[0127] The present invention also concerns a method of treating advanced breast cancer in a mammal, particularly a woman, comprising the step of administering a therapeutically effective amount of a farnesyl protein tranferase inhibitor to said mammal.

[0128] In particular, the present invention is concerned with the use of at least a farnesyl protein transferase inhibitor for the preparation of a pharmaceutical composition for treating advanced breast cancer, wherein said farnesyl protein transferase inhibitor is a compound of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) above, more particularly a compound of formula (I), (II) or (III): 10

[0129] the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein

[0130] the dotted line represents an optional bond;

[0131] X is oxygen or sulfur;

[0132] R.sup.1 is hydrogen, C.sub.1-12alkyl, Ar.sup.1, Ar.sup.2C.sub.1-6alkyl, quinolinylC.sub.1-6alkyl, pyridylC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkyl, aminoC.sub.1-6alkyl,

[0133] or a radical of formula -Alk.sup.1-C(.dbd.O)-R.sup.9, -Alk.sup.1-S(O)-R.sup.9 or -Alk.sup.1-S(O).sub.2-R.sup.9,

[0134] wherein Alk.sup.1 is C.sub.1-6alkanediyl,

[0135] R.sup.9 is hydroxy, C.sub.1-6alkyl, C.sub.1-6alkyloxy, amino, C.sub.1-8alkylamino or C.sub.1-8alkylamino substituted with C.sub.1-6alkyloxycarbonyl;

[0136] R.sup.2, R.sub.3 and R.sub.16 each independently are hydrogen, hydroxy, halo, cyano, C.sub.1-6alkyl, C.sub.1-6alkyloxy, hydroxyC.sub.1-6alkyloxy, C.sub.1-6alkyloxyC.sub.1-6alkyloxy, aminoC.sub.1-6alkyloxy, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkyloxy- , Ar.sup.1, Ar.sup.2C.sub.1-6alkyl, Ar.sup.2oxy, Ar.sup.2C.sub.1-6alkyloxy- , hydroxycarbonyl, C.sub.1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C.sub.2-6alkenyl, 4,4-dimethyloxazolyl; or

[0137] when on adjacent positions R.sup.2 and R.sup.3 taken tog ether may form a bivalent radical of formula

--O--CH.sub.2--O-- (a-1),

--O--CH.sub.2--CH.sub.2--O-- (a-2),

--O--CH.dbd.CH-- (a-3),

--O--CH.sub.2--CH.sub.2-- (a-4),

--O--CH.sub.2--CH.sub.2--CH.sub.2-- (a-5), or

--CH.dbd.CH--CH.dbd.CH-- (a-6);

[0138] R.sup.4 and R.sup.5 each independently are hydrogen, halo, Ar.sup.1, C.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1- -6alkyl, C.sub.1-6alkyloxy, C.sub.1-6alkylthio, amino, hydroxycarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylS(O)C.sub.1-6alkyl or C.sub.1-6alkylS(O).sub.2C.sub.1-6alkyl;

[0139] R.sup.6 and R.sup.7 each independently are hydrogen, halo, cyano, C.sub.1-6alkyl, C.sub.1-6alkyloxy, Ar.sup.2oxy, trihalomethyl, C.sub.1-6alkylthio, di(C.sub.1-6alkyl)amino, or

[0140] when on adjacent positions R.sup.6 and R.sup.7 taken together may form a bivalent radical of formula

--O--CH.sub.2--O-- (c-1), or

--CH.dbd.CH--CH.dbd.CH-- (c-2);

[0141] R.sup.8 is hydrogen, C.sub.1-6alkyl, cyano, hydroxycarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylcarbonylC.sub.1-6alkyl, cyanoC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.1-6alkyl, carboxyC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, aminoC.sub.1-6alkyl, mono- or di(C.sub.1-6alkyl)aminoC.sub.1-6alkyl, imidazolyl, haloC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, aminocarbonylC.sub.1-6alkyl, or a radical of formula

--O--R.sup.10 (b-1),

--S--R.sup.10 (b-2),

--N--R.sup.11R.sup.12 (b-3),

[0142] wherein R.sup.10is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, Ar.sup.1, Ar.sup.2C.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.1-6alkyl, or a radical or formula -Alk.sup.2-OR.sup.13 or -Alk.sup.2-NR.sup.14R.sup.15;

[0143] R.sup.11 is hydrogen, C.sub.1-12alkyl, Ar.sup.1 or Ar.sup.2C.sub.1-6alkyl;

[0144] R.sup.12 is hydrogen, C.sub.1-6alkyl, C.sub.1-16alkylcarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylaminocarbonyl, Ar.sup.1, Ar.sup.2C.sub.1-6alkyl, C.sub.1-6alkylcarbonylC.sub.1-6alkyl, a natural amino acid, Ar.sup.1carbonyl, Ar.sup.2C.sub.1-6alkylcarbonyl, aminocarbonylcarbonyl, C.sub.1-6alkyloxyC.sub.1-6alkylcarbonyl, hydroxy, C.sub.1-6alkyloxy, aminocarbonyl, di(C.sub.1-6alkyl)aminoC.sub.1-6alkylca- rbonyl, amino, C.sub.1-6alkylamino, C.sub.1-6alkylcarbonylamino,

[0145] or a radical or formula -Alk.sup.2-OR.sup.13 or -Alk.sup.2-NR.sup.14R.sup.15;

[0146] wherein Alk.sup.2 is C.sub.1-6alkanediyl;

[0147] R.sup.13 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, hydroxyC.sub.1-6alkyl, Ar.sup.1 or Ar.sup.2C.sub.1-6alkyl;

[0148] R.sup.14 is hydrogen, C.sub.1-6alkyl, Ar.sup.1 or Ar.sup.2C.sub.1-6alkyl;

[0149] R.sup.15 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, Ar.sup.1 or Ar.sup.2C.sub.1-6alkyl:

[0150] R.sup.17 is hydrogen, halo, cyano, C.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl, Ar.sup.1;

[0151] R.sup.18 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkyloxy or halo;

[0152] R.sup.19 is hydrogen or C.sub.1-6alkyl;

[0153] Ar.sup.1 is phenyl or phenyl substituted with C.sub.1-6alkyl, hydroxy, amino, C.sub.1-6alkyloxy or halo; and

[0154] Ar.sup.2 is phenyl or phenyl substituted with C.sub.1-6alkyl, hydroxy, amino, C.sub.1-6alkyloxy or halo.

[0155] In Formulas (I), (II) and (III), R.sup.4 or R.sup.5 may also be bound to one of the nitrogen atoms in the imidazole ring. In that case the hydrogen on the nitrogen is replaced by R.sup.4 or R.sup.5 and the meaning of R.sup.4 and R.sup.5 when bound to the nitrogen is limited to hydrogen, Ar.sup.1, C.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylS(O)C.sub.1-6alkyl, C.sub.1-6alkylS(O).sub.2C.sub.1-6alkyl.

[0156] Preferably the substituent R.sup.18 is situated on the 5 or 7 position of the quinolinone moiety and substituent R.sup.19 is situated on the 8 position when R.sup.18 is on the 7-position.

[0157] Interesting compounds are these compounds of formula (I) wherein X is oxygen.

[0158] Also interesting compounds are these compounds of formula (I) wherein the dotted line represents a bond, so as to form a double bond.

[0159] Another group of interesting compounds are those compounds of formula (I) wherein R.sup.1 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, di(C.sub.1-6alkyl)aminoC.sub.1-6alkyl, or a radical of formula -Alk.sup.1-C(.dbd.O)-R.sup.9, wherein Alk.sup.1 is methylene and R.sup.9 is C.sub.1-8alkylamino substituted with C.sub.1-6alkyloxycarbonyl.

[0160] Still another group of interesting compounds are those compounds of formula (I) wherein R.sup.3 is hydrogen or halo; and R.sup.2 is halo, C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.1-6alkyloxy, trihalomethoxy or hydroxyC.sub.1-6alkyloxy.

[0161] A further group of interesting compounds are those compounds of formula (I) wherein R.sup.2 and R.sup.3 are on adjacent positions and taken together to form a bivalent radical of formula (a-1), (a-2) or (a-3).

[0162] A still further group of interesting compounds are those compounds of formula (I) wherein R.sup.5 is hydrogen and R.sup.4 is hydrogen or C.sub.1-6alkyl.

[0163] Yet another group of interesting compounds are those compounds of formula (I) wherein R.sup.7 is hydrogen; and R.sup.6 is C.sub.1-6alkyl or halo, preferably chloro, especially 4-chloro.

[0164] A particular group of compounds are those compounds of formula (1) wherein R.sup.8 is hydroxy, haloC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, cyanoC.sub.1-6alkyl, C.sub.1-6alkyloxy-carbonylC.sub.1-6alkyl, imidazolyl, or a radical of formula -NR.sup.11R.sup.12 wherein R.sup.11 is hydrogen or C.sub.1-12alkyl and R.sup.12 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkyloxy, hydroxy, C.sub.1-6alkyloxyC.sub.1-6alkylcarbonyl, or a radical of formula -Alk.sup.2-OR.sup.13 wherein R.sup.13 is hydrogen or C.sub.1-6alkyl.

[0165] Preferred compounds are those compounds wherein R.sup.1 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, di(C.sub.1-6alkyl)aminoC.sub.1-6alkyl, or a radical of formula -Alk.sup.1-C(.dbd.O)-R.sup.9, wherein Alk.sup.1 is methylene and R.sup.9 is C.sub.1-8alkylamino substituted with C.sub.1-6alkyloxycarbonyl; R.sup.2 is halo, C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.1-6alkyloxy, trihalomethoxy, hydroxyC.sub.1-6alkyloxy or Ar.sup.1; R.sup.3 is hydrogen; R.sup.4 is methyl bound to the nitrogen in 3-position of the imidazole; R.sup.5 is hydrogen; R.sup.6 is chloro; R.sup.7 is hydrogen; R.sup.8 is hydrogen, hydroxy, haloC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, cyanoC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.1-6alkyl, imidazolyl, or a radical of formula --NR.sup.11R.sup.12 wherein R.sup.11 is hydrogen or C.sub.1-12alkyl and R.sup.12 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkyloxy, C.sub.1-6alkyloxyC.sub.1-6alkylcarbonyl, or a radical of formula -Alk.sup.2-OR.sup.13 wherein R.sup.13 is C.sub.1-6alkyl: R.sup.17 is hydrogen and R.sup.18 is hydrogen.

[0166] Most preferred compounds are

[0167] 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-- 5-yl)methyl]-1-methyl-2(1H)-quinolinone,

[0168] 6-[amino(4-chlorophenyl)-1-methyl-1H-imidazol-5-ylmethyl]-4-(3-chlo- rophenyl)-1-methyl-2(1h)-quinolinone;

[0169] 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-e- thoxyphenyl)-1-methyl-2(1H)-quinolinone;

[0170] 6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethoxyph- enyl)-1-methyl-2(1H)-quinolinone monohydrochloride.monohydrate;

[0171] 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-eth- oxyphenyl)-1-methyl-2(1 H)-quinolinone,

[0172] 6-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-- 4-(3-propylphenyl)-2(1H)-quinolinone; a stereoisomeric form thereof or a pharmaceutically acceptable acid or base addition salt; and

[0173] (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3- -chlorophenyl)-1-methyl-2(1H)-quinolinone (Compound 75 in Table 1 of the Experimental part of WO-97/21701); or a pharmaceutically acceptable acid addition salt thereof. The latter compound is especially preferred.

[0174] Further preferred embodiments of the present invention include compounds of formula (IX) wherein one or more of the following restrictions apply:

[0175] .dbd.X.sup.1-X.sup.2-X.sup.3 is a trivalent radical of formula (x-1), (x-2), (x-3), (x-4) or (x-9) wherein each R.sup.6 independently is hydrogen, C.sub.1-4alkyl, C.sub.1-4alkyloxycarbonyl, amino or aryl and R.sup.7 is hydrogen;

[0176] >Y.sup.1-Y.sup.2- is a trivalent radical of formula (y-1), (y-2), (y-3), or (y-4) wherein each R.sup.9 independently is hydrogen, halo, carboxyl, C.sub.1-4alkyl or C.sub.1-4alkyloxycarbonyl;

[0177] r is 0, 1 or 2;

[0178] s is 0 or 1;

[0179] t is 0;

[0180] R.sup.1 is halo, C.sub.1-6alkyl or two R.sup.1 substituents ortho to one another on the phenyl ring may independently form together a bivalent radical of formula (a-1);

[0181] R.sup.2 is halo;

[0182] R.sup.3 is halo or a radical of formula (b-1) or (b-3) wherein

[0183] R.sup.10 is hydrogen or a radical of formula -Alk-OR.sup.13,

[0184] R.sup.11 is hydrogen;

[0185] R.sup.12 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, hydroxy, C.sub.1-6alkyloxy or mono- or

[0186] di(C.sub.1-6alkyl)aminoC.sub.1-6alkylcarbonyl;

[0187] Alk is C.sub.1-6alkanediyl and R.sup.13 is hydrogen;

[0188] R.sup.4 is a radical of formula (c-1) or (c-2) wherein

[0189] R.sup.16 is hydrogen, halo or mono- or di(C.sub.1-4alkyl)amino;

[0190] R.sup.17 is hydrogen or C.sub.1-6alkyl;

[0191] aryl is phenyl.

[0192] A particular group of compounds consists of those compounds of formula (IX) wherein .dbd.X.sup.1-X.sup.2-X.sup.3 is a trivalent radical of formula (x-1), (x-2), (x-3), (x-4) or (x-9), >Y.sup.1-Y.sup.2 is a trivalent radical of formula (y-2), (y-3) or (y-4), r is 0 or 1, s is 1, t is 0, R.sup.1 is halo, C.sub.(1-4)alkyl or forms a bivalent radical of formula (a-1), R.sup.2 is halo or C.sub.1-4alkyl, R.sup.3 is hydrogen or a radical of formula (b-1) or (b-3), R.sup.4 is a radical of formula (c-1) or (c-2), R.sup.6 is hydrogen, C.sub.1-4alkyl or phenyl, R.sup.7 is hydrogen, R.sup.9 is hydrogen or C.sub.1-4alkyl, R.sup.10 is hydrogen or -Alk-OR.sup.13, R.sup.11 is hydrogen and R.sup.12 is hydrogen or C.sub.1-6alkylcarbonyl and R.sup.13 is hydrogen:

[0193] Preferred compounds are those compounds of formula (IX) wherein .dbd.X.sup.1-X.sup.2-X.sup.3 is a trivalent radical of formula (x-1) or (x-4). >Y.sup.1-Y.sup.2 is a trivalent radical of formula (y-4), r is 0 or 1, s is 1, t is 0, R.sup.1 is halo, preferably chloro and most preferably 3-chloro, R.sup.2 is halo, preferably 4-chloro or 4-fluoro, R.sup.3 is hydrogen or a radical of formula (b-1) or (b-3), R.sup.4 is a radical of formula (c-1) or (c-2), R.sup.6 is hydrogen, R.sup.7 is hydrogen, R.sup.9 is hydrogen, R.sup.10 is hydrogen, R.sup.11 is hydrogen and R.sup.12 is hydrogen;

[0194] Other preferred compounds are those compounds of formula (IX) wherein .dbd.X.sup.1-X.sup.2-X.sup.3 is a trivalent radical of formula (x-2), (x-3) or (x-4) >Y.sup.1-Y.sup.2 is a trivalent radical of formula (y-2), (y-3) or (y-4), r and s are 1, t is 0, R.sup.1 is halo, preferably chloro, and most preferably 3-chloro or R.sup.1 is C.sub.1-4alkyl, preferably 3-methyl, R.sup.2 is halo, preferably chloro, and most preferably 4-chloro, R.sup.3 is a radical of formula (b-1) or (b-3), R.sup.4 is a radical of formula (c-2), R.sup.6 is C.sub.1-4alkyl, R.sup.9 is hydrogen, R.sup.10 and R.sup.11 are hydrogen and R.sup.12 is hydrogen or hydroxy.

[0195] The most preferred compounds of formula (IX) are

[0196] 7-[(4-fluorophenyl)(1H-imidazol-1-yl)methyl]-5-phenylimidazo[1,2-a]- quinoline;

[0197] .alpha.-(4-chlorophenyl)-.alpha.-(1-methyl-1H-imidazol-5-yl)-5-phen- ylimidazo[1,2-a]quinoline-7-methanol;

[0198] 5-(3-chlorophenyl)-.alpha.-(4-chlorophenyl)-.alpha.-(1-methyl-1H-im- idazol-5-yl)-imidazo[1,2-a]quinoline-7-methanol;

[0199] 5-(3-chlorophenyl)-.alpha.-(4-chlorophenyl)-.alpha.-(1-methyl-1H-im- idazol-5-yl)imidazo[1,2-a]quinoline-7-methanamine;

[0200] 5-(3-chlorophenyl)-.alpha.-(4-chlorophenyl)-.alpha.-(1-methyl-1H-im- idazol-5-yl)tetrazolo[1,5-a]quinoline-7-methanamine;

[0201] 5-(3-chlorophenyl)-.alpha.-(4-chlorophenyl)-1-methyl-.alpha.-(1-met- hyl-1H-imidazol-5-yl)-1,2,4-triazolo[4,3-a]quinoline-7-methanol;

[0202] 5-(3-chlorophenyl)-.alpha.-(4-chlorophenyl)-.alpha.-(1-methyl-1H-im- idazol-5-yl)tetrazolo[1,5-a]quinoline-7-methanamine;

[0203] 5-(3-chlorophenyl)-.alpha.-(4-chlorophenyl)-.alpha.-(1-methyl-1H-im- idazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanol; 5-(3-chlorophenyl)-.alpha.-(4-chlorophenyl)-4,5-dihydro-.alpha.-(1-methyl- -1H-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanol;

[0204] 5-(3-chlorophenyl)-.alpha.-(4-chlorophenyl)-.alpha.-(1-methyl-1H-im- idazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine;

[0205] 5-(3-chlorophenyl)-.alpha.-(4-chlorophenyl)-N-hydroxy-.alpha.-(1-me- thyl-1H-imidazol-5-yl)tetrahydro[1,5-a]quinoline-7-methanamine;

[0206] .alpha.-(4-chlorophenyl)-.alpha.-(1-methyl-1H-imidazol-5-yl)-5-(3-m- ethylphenyl)tetrazolo[1,5-a]quinoline-7-methanamine; the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof.

[0207] 5-(3-chlorophenyl)-.alpha.-(4-chlorophenyl)-.alpha.-(1-methyl-1H-im- idazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine, especially the (-) enantiomer, and its pharmaceutically acceptable acid addition salts are especially preferred.

[0208] As used in the foregoing definitions and hereinafter halo defines fluoro, chloro, bromo and iodo; C.sub.1-6alkyl defines straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl and the like; C.sub.1-8alkyl encompasses the straight and branched chained saturated hydrocarbon radicals as defined in C.sub.1-6alkyl as well as the higher homologues thereof containing 7 or 8 carbon atoms such as, for example heptyl or octyl; C.sub.1-12alkyl again encompasses C.sub.1-8alkyl and the higher homologues thereof containing 9 to 12 carbon atoms, such as, for example, nonyl, decyl, undecyl, dodecyl; C.sub.1-16alkyl again encompasses C.sub.1-12alkyl and the higher homologues thereof containing 13 to 16 carbon atoms, such as, for example, tridecyl, tetradecyl, pentedecyl and hexadecyl; C.sub.2-6alkenyl defines straight and branched chain hydrocarbon radicals containing one double bond and having from 2 to 6 carbon atoms such as, for example, ethenyl, 2-propenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, and the like; C.sub.1-6alkanediyl defines bivalent straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms, such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl and the branched isomers thereof. The term "C(.dbd.O)" refers to a carbonyl group, "S(O)" refers to a sulfoxide and "S(O).sub.2" to a sulfon. The term "natural amino acid" refers to a natural amino acid that is bound via a covalent amide linkage formed by loss of a molecule of water between the carboxyl group of the amino acid and the amino group of the remainder of the molecule. Examples of natural amino acids are glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylanaline, tryptophan, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine.

[0209] The pharmnaceutically acceptable acid or base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and non-toxic base addition salt forms which the compounds of formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) are able to form. The compounds of formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) which have basic properties can be converted in their pharmaceutically acceptable acid addition salts by treating said base form with an appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.

[0210] The compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) which have acidic properties may be converted in their pharmaceutically acceptable base addition salts by treating said acid form with a suitable organic or inorganic base. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

[0211] The terms acid or base addition salt also comprise the hydrates and the solvent addition forms which the compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

[0212] The term stereochemically isomeric forms of compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) may possess. Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.

[0213] Some of the compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) may also exist in their tauromeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

[0214] Whenever used hereinafter, the term "compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX)" is meant to include also the pharmaceutically acceptable acid or base addition salts and all stereoisomeric forms.

[0215] Other farnesyl protein transferase inhibitors which can be employed in accordance with the present include Arglabin, perrilyl alcohol, SCH-66336, 2(S)-[2(S)-[2(R)-amino-3-mercapto]propylamino-3 (S)-methyl]-pentyloxy-3-phenylpropionyl-methionine sulfone (Merck); L778123, BMS 214662, Pfizer compounds A and B described above. These compounds can be prepared, for example, by methods described in the relevant patent specifications identified above which are incorporated herein by reference.

[0216] Farnesyl protein transferase inhibitors can be prepared and formulated into pharmaceutical compositions by methods known in the art and in particular according to the methods described in the published patent specifications mentioned herein and incorporated by reference; for the compounds of formulae (I), (II) and (III) suitable examples can be found in WO-97/21701. Compounds of formulae (IV), (V), and (VI) can be prepared and formulated using methods described in WO 97/16443. compounds of formulae (VII) and (VIII) according to methods described in WO 98/40383 and WO 98/49157 and compounds of formula (IX) according to methods described in WO 00/39082 respectively. To prepare the aforementioned pharmaceutical compositions, a therapeutically effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for systemic administration such as oral, percutaneous, or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions, or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable solutions containing compounds of formula (I) may be formulated in an oil for prolonged action. Appropriate oils for this purpose are, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soy bean oil, synthetic glycerol esters of long chain fatty acids and mixtures of these and other oils. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment. As appropriate compositions for topical application there may be cited all compositions usually employed for topically administering drugs e.g. creams, gellies, dressings, shampoos, tinctures, pastes, ointments, salves, powders and the like. Application of said compositions may be by aerosol, e.g. with a propellent such as nitrogen, carbon dioxide, a freon, or without a propellent such as a pump spray, drops, lotions, or a semisolid such as a thickened composition which can be applied by a swab. In particular, semisolid compositions such as salves, creams, gellies, ointments and the like will conveniently be used.

[0217] It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

[0218] Preferably, a therapeutically effective amount of the pharmnaceutical composition comprising a farnesyl protein transferase inhibitor is administered orally or parenterally. Said therapeutically effective amount is the amount that effectively prevents growth or reduces the size of breast cancer tumors in patients. On the basis of the current data, it appears that a pharmaceutical composition comprising a compound of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), and in particular (+)-6-[amino(4-chlorophenyl) (1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quin- olinone (compound 75) as the active ingredient can be administered orally in an amount of from 10 to 1500 mg daily, either as a single dose or subdivided into more than one dose. A preferred amount ranges from 100 to 1,000 mg daily. A particularly preferred dosage for such a compound is 300 mg administered twice daily. This treatment can be given either continuously or intermittently in cycles of 3-4 weeks with treatment given for 1-21 days per cycle.

[0219] Suitable dosages for the compounds Arglabin (WO98/28303), perrilyl alcohol (WO 99/45712), SCH-66336 (U.S. Pat. No. 5,874,442), L778123 (WO 00/01691), 2(S)-[2(S)-[2(R)-amino-3-mercapto]propylamino-3(S)-methyl]-pen- tyloxy-3-phenylpropionyl-methionine sulfone (WO94/10138), BMS 214662 (WO 97/30992), Pfizer compounds A and B (WO 00/12499 and WO 00/12498) are given in the aforementioned patent specifications which are incorporated herein by reference or are known to or can be readily determined by a person skilled in the art.

[0220] In relation to perrilyl alcohol, the medicament may be administered 1-4 g per day per 150 lb human patient. Preferably, 1-2 g per day per 150 lb human patient. SCH-66336 typically may be administered in a unit dose of about 0.1 mg to 100 mg, more preferably from about 1 mg to 300 mg according to the particular application. Compounds L778123 and 2(S)-[2(S)-[2(R)-amino-3-mercapto]propylamino-3(S)-methyl]-pentyloxy-3-ph- enylpropionyl-methionine sulfone may be administered to a human patient in an amount between about 0.1 mg/kg of body weight to about 20 mg/kg of body weight per day, preferably between 0.5 mg/kg of bodyweight to about 10 mg/kg of body weight per day.

[0221] Pfizer compounds A and B may be administered in dosages ranging from about 1.0 mg up to about 500 mg per day, preferably from about 1 to about 100 mg per day in single or divided (i.e. multiple) doses. Therapeutic compounds will ordinarly be administered in daily dosages ranging from about 0.01 to about 10 mg per kg body weight per day, in single or divided doses.

[0222] BMS 214662 may be administered in a dosage range of about 0.05 to 200 mg/kg/day, preferably less than 100 mg/kg/day in a single dose or in 2 to 4 divided doses.

[0223] The above farnesyl trasferase inhibitor may be used in combination with one or more other treatments for advanced breast cancer especially endocrine therapy such as an anti-estrogen agent such as an estrogen receptor antagonist or a selective estrogen receptor modulator or an aromatase inhibitor. A particularly preferred estrogen receptor antagonist is tamoxifen which has previously been widely used in the treatment of breast cancer. Other estrogen receptor antagonists or selective estrogen receptor modulators include toremifene, droloxifene, faslodex and raloxifene. Examples of aromatase inhibitors or inactivators include exemestane, anastrozole, letrazole and vorozole. Other anti-cancer agents which may be employed include platinum coordination compounds for example cisplatin or carboplatin, taxane compounds for example paclitaxel or docetaxel, camptothecin compounds for example irinotecan or topotecan, anti-tumor vinca alkaloids for example vinblastine, vincristine or vinorelbine, anti-tumor nucleoside derivatives for example 5-fluorouracil, gemcitabine or capecitabine, nitrogen mustard or nitrosourea alkylating agents for example cyclophosphamide, chlorambucil, carmustine or lomustine, anti-tumor anthracycline derivatives for example daunorubicin, doxorubicin, idarubicin or epirubicin; HER2 antibodies for example trastzumab; and anti-tumor podophyllotoxin derivatives for example etoposide or teniposide.

[0224] The farnesyl transferase inhibitor and the further anti-cancer agent may be administered simultaneously (e.g. in separate or unitary compositions) or sequentially in either order. In the latter case, the two compounds will be administered within a period and in an amount and manner that is sufficient to ensure that an advantageous or synergistic effect is achieved. It will be appreciated that the preferred method and order of administration and the respective dosage amounts and regimes for each component of the combination will depend on the particular farnesyl transferase inhibitor and further anti-cancer agents being administered, their route of administration, the particular tumor being treated and the particular host being treated. The optimum method and order of administration and the dosage amounts and regime can be readily determined by those skilled in the art using conventional methods and in view of the information set out herein.

Clinical Study

[0225] Compound 75 above, namely (+)-6-[amino(4-chlorophenyl) (1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quin- olinone was tested in patients with advanced breast cancer as described in the following account of a clinical study.

[0226] The clinical study involved 27 patients with advanced breast cancer. The median age of the patients was 59 years (range 35-80 years). Adjuvant chemo and/or endocrine therapy had been received by 15 and 16 patients respectively. Prior therapy for advanced disease included second-line hormonal therapy in 18 (67%) patients and/or one chemotherapy regimen only in 14 (52%) patients. Treatment was well tolerated, with myelosuppression the most frequent and dose-limiting toxicity. The first 6 patients treated with 400 mg of compound 75 b.i.d. developed grade 3/4 neutropenia after a median of 26 days; 5 were re-treated with dose reduction following neutrophil recovery without further haematological toxicity. The subsequent 21 patients received 300 mg of compound 75 b.i.d.; 6 (29%) developed grade 3/4 neutropenia after a median of 32 days, with one episode of fever. Neutrophil recovery occurred over 1-2 weeks in all cases. Thrombocytopenia (grade 3) occurred in 3 (11%) patients. Non-haematological toxicities included: grade 2/3 parasthesia/numbness in 7 (26%) patients occurring after a median of 10 weeks therapy; grade 2/3 diarrhoea in 3 (11%) patients; skin rash in 3 (11%); fatigue in 8 (28%). 26 patients were able to be evaluated for tumour response; 8 withdrew early (<12 weeks) due to either progression of disease and/or toxicity while 18 patients received at least 3 months treatment (range 12-36+ weeks). Tumour shrinkage of at least 50% in volume was seen in 3 (12%) patients, sites of response included liver, lung, lymph nodes and skin nodules. A further 9 (35%) patients had stable disease, i.e. no progression of tumour growth, at the 3 month evaluation. These results demonstrated that compound 75 has clinical activity in advanced breast cancer.

Glypican-1 in human breast cancer
Compositions and methods for therapy and diagnosis of breast cancer
Mammaglobin, a mammary-specific breast cancer protein
Method of diagnosing breast cancer and compositions therefor
Use of anastrozole for the treatment of post-menopausal women having early breast cancer
Compositions and methods for the therapy and diagnosis of breast cancer
Treatment of breast cancer
Apparatus and method for breast cancer imaging


20030092707 Treatment of breast cancer
20030087265 Specific microarrays for breast cancer screening
20030086934 Basal cell markers in breast cancer and uses thereof
20030077832 Methods and compositions for detection of breast cancer
20030072812 Breast cancer eradication program
20030064419 Proteins, genes and their use for diagnosis and treatment of breast cancer
20030059790 Method and kit for the prognostication of breast cancer
20030050470 Biomarkers and targets for diagnosis, prognosis and management of prostate disease, bladder and breast cancer
20030049660 P38 MAPK pathway predicts endocrine-resistant growth of human breast cancer and provides a novel diagnostic and treatment target
20020106347 Cytokines and their use in treatment and/or prophylaxis of breast cancer
20020102602 COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER AND METHODS FOR THEIR USE
20020098488 ATM mutations in breast cancer
20020090642 METHODS FOR DETERMINING THE PROGNOSIS OF BREAST CANCER USING ANTIBODIES SPECIFIC FOR THYMIDYLATE SYNTHASE
20020086341 Method of diagnosing breast cancer using nipple fluid
20020085998 Compositions and methods for the therapy and diagnosis of breast cancer
20020082216 Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
20020081609 Compositions and methods for the therapy and diagnosis of breast cancer
20020068285 Compositions and methods for the therapy and diagnosis of breast cancer
20020068036 Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
20020064872 Compositions and methods for the therapy and diagnosis of breast cancer
20020019418 Methods of preventing breast cancer
20020009738 Methods, compositions and kits for the detection and monitoring of breast cancer
20020006616 Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
20020004239 Genes differentially expressed in breast cancer
20010047033 Composition for and method of preventing or treating breast cancer

Copyright © 2006 - 2015 Patent Information Search